Blog Coverage Aurinia Chooses Worldwide Clinical Trials as CRO for AURORA Phase-3 Study of Voclosporin

Upcoming AWS Coverage on Incyte Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. blog coverage looks at the headline from Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) as the Company announced on January 27, 2017, that it had chosen Worldwide Clinical Trials as its CRO (Clinical Research Organization) for the AURORA Phase-3 Study of Voclosporin for the Treatment of Active Lupus Nephritis. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Aurinia Pharma’s competitors within the Biotechnology space, Incyte Corp. (NASDAQ: INCY), announced on January 24, 2017, that it will release its Q4 and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017. AWS will be initiating a research report on Incyte in the coming days.

Today, AWS is promoting its blog coverage on AUPH; touching on INCY. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=AUPH

http://www.activewallst.com/registration-3/?symbol=INCY

Victoria, British Columbia based Aurinia is a clinical biopharmaceutical company that works to develop and commercialize therapies to treat serious diseases with high unmet medical need. Aurinia is developing an investigational drug for the treatment of Lupus Nephritis (LN).

Worldwide Clinical Trials is a full-service contract research organization (CRO) that partners with pharmaceutical and biotechnology companies and assists them across the various stages of drug development from discovery to clinical development and commercialization. They are equipped to cover a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases.

Commenting on the partnership, Charles Rowland, CEO of Aurinia said:

“We are thrilled to partner with Worldwide to support the AURORA Phase-3 clinical trial. We are rapidly moving forward with our plans to bring this important therapy to market for patients living with this devastating disease, and Worldwide’s deep expertise and capabilities in managing pivotal trials will be a tremendous asset to us.”

Peter Benton, President and CEO of Worldwide Clinical Trials, added:

“Our entire Worldwide team is delighted to have been selected as Aurinia’s CRO partner to advance Voclosporin, which has the potential to become the first FDA-approved treatment for LN.”

About the disease – Lupus Nephritis

Lupus also known as System Lupus Erythematosus (SLE) is a chronic, complex and often disabling disorder that affects more than 500,000 people in the US, mostly women. SLE is an extremely heterogeneous disease which can affect the heart, lungs, skin, joints, vascular system, and kidneys.

Lupus Nephritis (LN) in an inflammation of the kidney that represents a serious progression of SLE. It is estimated that as many as 60% of all SLE patients have clinical LN requiring treatment. LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease, which makes it a serious and potentially life-threatening condition. Currently, there is no FDA approved therapy for treatment for LN.

About the drug Voclosporin

Voclosporin is an investigational drug and a novel and potentially best-in-class calcineurin inhibitor (CNI). Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the US Food & Drug Administration (FDA). It has the potential to become the first approved treatment for LN in the US and Europe. The Company expects that once the drug gets FDA approval it would enjoy patent protection in US and other markets including Europe and Japan till October 2027.

The AURORA Study

The AURORA is a 52-week global double-blind Phase-3 study. The aim of the study is to investigate whether Voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 24 weeks. The trial is being conducted on approximately 320 patients. The primary aim of the trial is that by the end of week 24, participants in the trial should achieve renal response.

Brief Background and Way Forward

In November 2016, Aurinia had announced that it planned to initiate a single, Phase-3 clinical trial (AURORA) which is designed similarly to that of their ongoing AURA clinical trial. The single Phase-3 clinical trial is for use of Voclosporin in the treatment of lupus nephritis (LN). The announcement was made following Aurinia’s successful End of Phase-2 meeting with the US FDA Division of Pulmonary, Allergy and Rheumatology Products. On completing the Phase-3 trials, Aurinia plans to use data from both the AURA and AURORA trials for the applying for a New Drug Application (NDA). Since that time, Aurinia is on a tight schedule to ensure that its team is ready to execute a successful clinical trial. It focused on finalizing the study protocol and regulatory submissions along with site selection and necessary investments so that it can reach its goal. Aurinia has plans to start the Phase-3 AURORA trials in Q2 2017.

The selection of Worldwide as its CRO is the first step in this direction. With the partnership with Worldwide Aurinia will be able to move forward on the 52-week Phase-3 AURORA trials on approximately 320 patients. The experts at Worldwide will work closely with Aurinia’s Robert Huizinga, VP of Clinical Development and Rashieda Gluck, VP of Clinical Operations, for completing the AURORA study successfully.

The estimated date of completion of the final data collection of the study to measure the primary outcome is December 2019. The study is expected to be completed by March 2020.

Stock Performance

Aurinia Pharma’s share price finished last Friday’s trading session at $3.22, jumping 5.57%. A total volume of 7.00 million shares exchanged hands, which was higher than the 3 months average volume of 1.57 million shares. The stock has surged 50.47% and 54.07% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have soared 53.33%. The stock currently has a market cap of $124.92 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453788